Abstract
The discovery of IL‐17 and of the Th17 pathway has been a step in the classification of human diseases. Th17 targeting appears rather straightforward in diseases associated with inflammation and matrix destruction, such as rheumatoid arthritis, psoriasis, and Crohn's disease. In other conditions where IL‐17 is expressed and Th17 activated, it is unclear whether this is a primary or secondary event, making the use of Th17 inhibitors less obvious.
Funding Information
  • Hospices Civils de Lyon and the Région Rhône-Alpes

This publication has 40 references indexed in Scilit: